Pretax income is the income that a company earns before paying income taxes. ANI Pharmaceuticals's pretax income for the
three
months ended in Sep. 2024 was $-31.5 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-7.5 Mil.
ANI Pharmaceuticals's pretax margin was -21.23%.
During the past 13 years, ANI Pharmaceuticals's highest Pretax Margin was 34.62%. The lowest was -25.94%. And the median was 5.42%.
ANI Pharmaceuticals Pre-Tax Income Historical Data
The historical data trend for ANI Pharmaceuticals's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ANI Pharmaceuticals's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's Pre-Tax Income falls into.
ANI Pharmaceuticals Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
ANI Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (NAS:ANIP) Pre-Tax Income Explanation
ANI Pharmaceuticals's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 13 years, ANI Pharmaceuticals's highest Pretax Margin was 34.62%. The lowest was -25.94%. And the median was 5.42%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of ANI Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANIP has been successfully added to your 